# QT Imaging Holdings, Inc.: financial statements, quarterly

QTI · Nasdaq · CIK 1844505 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/qti.md) · [Financials](/companies/qti/financials.md) · [Filings](/companies/qti/filings.md) · [Insiders](/companies/qti/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/qti/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001844505-24-000077.md) | [0.0 d](/filings/0001844505-25-000038.md) | [1.4](/filings/0001844505-25-000053.md) | [1.7](/filings/0001844505-25-000083.md) | [1.0](/filings/0001628280-25-051332.md) | [0.8 d](/filings/0001628280-26-020909.md) | [2.8](/filings/0001628280-26-034381.md) | [3.7](/filings/0001628280-26-056182.md) | [4.2](/filings/0001628280-25-051332.md) | [8.3 d](/filings/0001628280-26-020909.md) | [6.5](/filings/0001628280-26-034381.md) | [7.4](/filings/0001628280-26-056182.md) |
| Cost of revenue | $m | [0.0](/filings/0001844505-24-000077.md) | [0.1 d](/filings/0001844505-25-000038.md) | [0.6](/filings/0001844505-25-000053.md) | [0.8](/filings/0001844505-25-000083.md) | [0.4](/filings/0001628280-25-051332.md) | [0.4 d](/filings/0001628280-26-020909.md) | [1.0](/filings/0001628280-26-034381.md) | [1.8](/filings/0001628280-26-056182.md) | [2.4](/filings/0001628280-25-051332.md) | [5.1 d](/filings/0001628280-26-020909.md) | [3.9](/filings/0001628280-26-034381.md) | [4.4](/filings/0001628280-26-056182.md) |
| Gross profit | $m | [0.0](/filings/0001844505-24-000077.md) | [(0.1) d](/filings/0001844505-25-000038.md) | [0.8](/filings/0001844505-25-000053.md) | [0.9](/filings/0001844505-25-000083.md) | [0.6](/filings/0001628280-25-051332.md) | [0.4 d](/filings/0001628280-26-020909.md) | [1.8](/filings/0001628280-26-034381.md) | [1.8](/filings/0001628280-26-056182.md) | [1.8](/filings/0001628280-25-051332.md) | [3.1 d](/filings/0001628280-26-020909.md) | [2.7](/filings/0001628280-26-034381.md) | [3.1](/filings/0001628280-26-056182.md) |
| Research and development | $m | [0.3](/filings/0001844505-24-000077.md) | [0.4 d](/filings/0001844505-25-000038.md) | [0.6](/filings/0001844505-25-000053.md) | [0.9](/filings/0001844505-25-000083.md) | [0.9](/filings/0001628280-25-051332.md) | [0.8 d](/filings/0001628280-26-020909.md) | [0.9](/filings/0001628280-26-034381.md) | [0.9](/filings/0001628280-26-056182.md) | [0.9](/filings/0001628280-25-051332.md) | [1.2 d](/filings/0001628280-26-020909.md) | [1.7](/filings/0001628280-26-034381.md) | [1.6](/filings/0001628280-26-056182.md) |
| Selling, general and administrative | $m | [0.9](/filings/0001844505-24-000077.md) | [0.4 d](/filings/0001844505-25-000038.md) | [5.7](/filings/0001844505-25-000053.md) | [2.2](/filings/0001844505-25-000083.md) | [2.0](/filings/0001628280-25-051332.md) | [1.7 d](/filings/0001628280-26-020909.md) | [2.0](/filings/0001628280-26-034381.md) | [2.0](/filings/0001628280-26-056182.md) | [2.5](/filings/0001628280-25-051332.md) | [2.6 d](/filings/0001628280-26-020909.md) | [3.3](/filings/0001628280-26-034381.md) | [3.3](/filings/0001628280-26-056182.md) |
| Operating income | $m | [(1.2)](/filings/0001844505-24-000077.md) | [(0.8) d](/filings/0001844505-25-000038.md) | [(5.6)](/filings/0001844505-25-000053.md) | [(2.2)](/filings/0001844505-25-000083.md) | [(2.3)](/filings/0001628280-25-051332.md) | [(2.1) d](/filings/0001628280-26-020909.md) | [(1.0)](/filings/0001628280-26-034381.md) | [(1.0)](/filings/0001628280-26-056182.md) | [(1.7)](/filings/0001628280-25-051332.md) | [(0.7) d](/filings/0001628280-26-020909.md) | [(2.3)](/filings/0001628280-26-034381.md) | [(1.9)](/filings/0001628280-26-056182.md) |
| Interest expense | $m | [0.1](/filings/0001193125-23-277144.md) | [0.1 d](/filings/0001193125-24-075608.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.1](/filings/0001193125-23-277144.md) | [(0.3) d](/filings/0001844505-25-000038.md) | not reported | [0.0](/filings/0001844505-25-000083.md) | [0.0](/filings/0001628280-25-051332.md) | [(0.0) d](/filings/0001628280-26-020909.md) | not reported | [0.0](/filings/0001628280-26-056182.md) | [0.0](/filings/0001628280-25-051332.md) | [(0.0) d](/filings/0001628280-26-020909.md) | not reported | [0.0](/filings/0001628280-26-056182.md) |
| Net income | $m | [(1.4)](/filings/0001844505-24-000077.md) | [(1.5) d](/filings/0001844505-25-000038.md) | [(0.6)](/filings/0001844505-25-000053.md) | [(1.2)](/filings/0001844505-25-000083.md) | [(3.6)](/filings/0001628280-25-051332.md) | [(3.5) d](/filings/0001628280-26-020909.md) | [(11.1)](/filings/0001628280-26-034381.md) | [(4.0)](/filings/0001628280-26-056182.md) | [(4.6)](/filings/0001628280-25-051332.md) | [(1.4) d](/filings/0001628280-26-020909.md) | [(3.4)](/filings/0001628280-26-034381.md) | [(11.1)](/filings/0001628280-26-056182.md) |
| Diluted EPS | $ per share | [(0.14)](/filings/0001844505-24-000077.md) | not reported | [(0.05)](/filings/0001844505-25-000053.md) | [(0.30)](/filings/0001844505-25-000083.md) | [(0.51)](/filings/0001628280-25-051332.md) | not reported | [(1.21)](/filings/0001628280-26-034381.md) | [(0.42)](/filings/0001628280-26-056182.md) | [(0.47)](/filings/0001628280-25-051332.md) | not reported | [(0.25)](/filings/0001628280-26-034381.md) | [(0.75)](/filings/0001628280-26-056182.md) |
| Basic EPS | $ per share | [(0.14)](/filings/0001844505-24-000077.md) | not reported | [(0.05)](/filings/0001844505-25-000053.md) | [(0.30)](/filings/0001844505-25-000083.md) | [(0.51)](/filings/0001628280-25-051332.md) | not reported | [(1.21)](/filings/0001628280-26-034381.md) | [(0.42)](/filings/0001628280-26-056182.md) | [(0.47)](/filings/0001628280-25-051332.md) | not reported | [(0.25)](/filings/0001628280-26-034381.md) | [(0.75)](/filings/0001628280-26-056182.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.1](/filings/0001193125-23-277144.md) | [0.2](/filings/0001844505-25-000038.md) | [5.6](/filings/0001844505-24-000013.md) | [4.6](/filings/0001844505-24-000045.md) | [1.5](/filings/0001844505-24-000077.md) | [1.2](/filings/0001628280-26-020909.md) | [3.0](/filings/0001844505-25-000053.md) | [2.0](/filings/0001628280-26-056182.md) | [1.7](/filings/0001628280-25-051332.md) | [10.4](/filings/0001628280-26-056182.md) | [6.9](/filings/0001628280-26-034381.md) | [10.9](/filings/0001628280-26-056182.md) |
| Current assets | $m | [0.1](/filings/0001193125-23-277144.md) | [4.8](/filings/0001844505-25-000038.md) | [11.4](/filings/0001844505-24-000013.md) | [9.5](/filings/0001844505-24-000045.md) | [5.8](/filings/0001844505-24-000077.md) | [4.9](/filings/0001628280-26-020909.md) | [9.8](/filings/0001844505-25-000053.md) | [10.7](/filings/0001844505-25-000083.md) | [11.3](/filings/0001628280-25-051332.md) | [22.1](/filings/0001628280-26-056182.md) | [21.2](/filings/0001628280-26-034381.md) | [29.4](/filings/0001628280-26-056182.md) |
| Total assets | $m | [23.1](/filings/0001193125-23-277144.md) | [6.7](/filings/0001844505-25-000038.md) | [12.9](/filings/0001844505-24-000013.md) | [10.8](/filings/0001844505-24-000045.md) | [7.0](/filings/0001844505-24-000077.md) | [6.1](/filings/0001628280-26-020909.md) | [10.9](/filings/0001844505-25-000053.md) | [11.6](/filings/0001844505-25-000083.md) | [12.1](/filings/0001628280-25-051332.md) | [23.0](/filings/0001628280-26-056182.md) | [22.0](/filings/0001628280-26-034381.md) | [30.6](/filings/0001628280-26-056182.md) |
| Current liabilities | $m | [8.9](/filings/0001193125-23-277144.md) | [7.3](/filings/0001844505-25-000038.md) | [4.4](/filings/0001844505-24-000013.md) | [15.3](/filings/0001844505-24-000045.md) | [5.4](/filings/0001844505-24-000077.md) | [9.8](/filings/0001628280-26-020909.md) | [5.3](/filings/0001844505-25-000053.md) | [6.3](/filings/0001844505-25-000083.md) | [12.7](/filings/0001628280-25-051332.md) | [7.9](/filings/0001628280-26-056182.md) | [8.5](/filings/0001628280-26-034381.md) | [9.5](/filings/0001628280-26-056182.md) |
| Total liabilities | $m | [11.7](/filings/0001193125-23-277144.md) | [12.0](/filings/0001844505-25-000038.md) | [17.8](/filings/0001844505-24-000013.md) | [16.9](/filings/0001844505-24-000045.md) | [16.6](/filings/0001844505-24-000077.md) | [15.6](/filings/0001628280-26-020909.md) | [31.1](/filings/0001844505-25-000053.md) | [12.0](/filings/0001844505-25-000083.md) | [21.2](/filings/0001628280-25-051332.md) | [16.6](/filings/0001628280-26-056182.md) | [18.2](/filings/0001628280-26-034381.md) | [28.4](/filings/0001628280-26-056182.md) |
| Long-term debt | $m | not reported | not reported | [11.7](/filings/0001844505-24-000013.md) | [11.7](/filings/0001844505-24-000045.md) | [10.5](/filings/0001844505-24-000077.md) | [9.9](/filings/0001844505-25-000038.md) | [10.2](/filings/0001844505-25-000053.md) | [10.1](/filings/0001844505-25-000083.md) | [15.1](/filings/0001628280-25-051332.md) | [10.1](/filings/0001628280-26-020909.md) | [10.1](/filings/0001628280-26-034381.md) | [11.4](/filings/0001628280-26-056182.md) |
| Shareholders' equity | $m | [(4.5)](/filings/0001844505-24-000077.md) | [(5.3)](/filings/0001628280-26-020909.md) | [(4.9)](/filings/0001844505-25-000083.md) | [(6.2)](/filings/0001628280-25-051332.md) | [(9.7)](/filings/0001628280-25-051332.md) | [(9.5)](/filings/0001628280-26-056182.md) | [(20.2)](/filings/0001628280-26-056182.md) | [(0.3)](/filings/0001628280-26-056182.md) | [(9.1)](/filings/0001628280-25-051332.md) | [6.4](/filings/0001628280-26-056182.md) | [3.8](/filings/0001628280-26-056182.md) | [2.2](/filings/0001628280-26-056182.md) |

- Cash and equivalents: us-gaap:Cash, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(444) d](/filings/0001844505-24-000077.md) | [(685) d](/filings/0001844505-25-000038.md) | [(5,976)](/filings/0001844505-25-000053.md) | [(980) d](/filings/0001844505-25-000083.md) | [(1,851) d](/filings/0001628280-25-051332.md) | [(1,227) d](/filings/0001628280-26-020909.md) | [(3,536)](/filings/0001628280-26-034381.md) | [(1,443) d](/filings/0001628280-26-056182.md) | [(879) d](/filings/0001628280-25-051332.md) | [(3,101) d](/filings/0001628280-26-020909.md) | [(3,654)](/filings/0001628280-26-034381.md) | [(4,837) d](/filings/0001628280-26-056182.md) |
| Capital expenditure | $k | [24.9 d](/filings/0001844505-24-000077.md) | [(13.0) d](/filings/0001844505-25-000038.md) | not reported | not reported | [7.6 d](/filings/0001628280-25-051332.md) | [53.4 d](/filings/0001628280-26-020909.md) | [0.0](/filings/0001628280-26-034381.md) | [47.0 d](/filings/0001628280-26-056182.md) | [(0.2) d](/filings/0001628280-25-051332.md) | [77.2 d](/filings/0001628280-26-020909.md) | [17.0](/filings/0001628280-26-034381.md) | [174 d](/filings/0001628280-26-056182.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [6.5](/filings/0001193125-23-277144.md) | [9.5](/filings/0001844505-24-000013.md) | [9.5](/filings/0001844505-24-000045.md) | [9.5](/filings/0001844505-24-000077.md) | [13.2](/filings/0001844505-25-000053.md) | [21.4](/filings/0001844505-25-000083.md) | [7.2](/filings/0001628280-25-051332.md) | [9.2](/filings/0001628280-26-034381.md) | [9.5](/filings/0001628280-26-056182.md) | [9.6](/filings/0001628280-25-051332.md) | [13.8](/filings/0001628280-26-034381.md) | [14.8](/filings/0001628280-26-056182.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 14,636,524 at 2026-08-12, from the cover of the [10-Q filed 2026-08-12](/filings/0001628280-26-056182.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.